Raymond James Financial
AMLX icon

Raymond James Financial’s Amylyx Pharmaceuticals AMLX Stock Holding History

Raymond James Financial’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-104
Closed -$667 – 5024
2025
Q2 		$667 Buy
+104
New +$506 ﹤0.01% 6632

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Raymond James Financial's AMLX Position: Q3 2025 in Review

Raymond James Financial sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 104 shares — an estimated $667 sold.

Raymond James Financial first reported a position in AMLX in Q2 2025 and held it in 1 quarter. The position peaked at $667 in Q2 2025. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

  • Raymond James Financial reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 104 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $667.
  • Raymond James Financial first reported a position in Amylyx Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Amylyx Pharmaceuticals position peaked at $667 in Q2 2025.
  • 169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.